Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 42

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 42
---
 Ventures is currently developing several clinical
assets that are in the pre-clinical stage. In June 2023, the original agreement was amended to increase the royalty payments and expand
the patent rights licensed. See Item 10. C “ Material contracts” for further information.

In March 2023, we acquired
Pharma15 Corporation (“ Pharma15”), a private US-based company that is developing next-generation therapeutic radiopharmaceuticals
for prostate cancer. Pharma15 was founded by radiopharmaceutical scientist Professor David Ulmert and Suzanne Dance. Pharma15 is developing
assets that seek to overcome resistance to prostate-specific membrane antigen (PSMA) targeting cancer therapies currently available or
in late-stage development. In each case, the technologies are designed to exhibit highly specific targeting of receptors expressed on
cancer cells, but not in healthy tissues. This selectivity may further limit toxicity in the new approaches to targeted radiotherapy in
prostate cancer.

In June 2024, we entered into
an equity agreement with Lantheus Omega, LLC (“ Lantheus Omega”), a wholly-owned subsidiary of Lantheus Holdings, Inc. (“ Lantheus
Holdings”), a leading radiopharmaceutical company. Under the terms of the agreement, Lantheus Omega purchased 149,625,180 ordinary
shares for A$7.5 million.

In September 2024, we entered
into a Master Service Agreement with AtomVie Global Radiopharma Inc. (“ AtomVie”). Under the terms of the agreement, AtomVie
will perform services relating to the development and manufacturing of 177Lu-BetaBart, a 177Lutetium-conjugated B7-H3 targeting radioantibody.
See Item 10. C “ Material contracts” for further information.

In June 2024, we entered into
a transfer and development agreement with Lantheus Omega. Under the terms of the transfer and development agreement, we transferred two
early pre-clinical assets, specifically the TROP2 and DUNP19 clinical assets, in exchange for a payment of A$3 million. The assignment
of the licenses and rights will require Radiopharm to amend the clinical asset arising from the Exclusive License Agreement, July 9, 2021,
with NanoMab Technology Limited. See Item 10. C “ Material contracts” for further information. Radiopharm completed the
assignment of the DUNP19 assets to Lantheus Omega, thus terminating the